Navigation Links
CEL-SCI Corporation Announces 2008 Financial Results
Date:1/14/2009

VIENNA, Va., Jan. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION

(NYSE Alternext US: CVM) reports financial results for the fiscal year ended September 30, 2008.

CEL-SCI reported a net loss for fiscal year 2008 of $(7,703,415) versus a net loss of $(9,629,657) in fiscal year 2007. The loss per share per common share for fiscal year 2008 was $(0.07) compared to a net loss per common share in fiscal year 2007 of $(0.10). Included in the loss in 2008 were non-cash expenditures that added up to approximately $3.3 million, including $1.3 million for employee-stock compensation charges and $1.4 million for various consulting and other related expenses.

The net loss included research and development (R&D) expenses of $4,101,563 in 2008 compared to $2,528,528 in 2007. R&D expenses increased due to higher costs associated with preparing for the Company's upcoming Phase III clinical trial of its cancer drug Multikine.

Geert Kersten, Chief Executive Officer said, "We are pleased by the progress we made in fiscal 2008 in preparing for our pivotal trial of Multikine for head and neck cancer. Expenditures for 2009 are expected to be significantly reduced because of the completion of the manufacturing facility and other material reductions in expenditures. Our focus now is to secure strategic partners to assist us in funding the Phase III study of our cancer drug."

The report by the Company's accountants also contained a "going concern" qualification. This means that based upon only the existing and committed amount of cash in CEL-SCI today, the accountants cannot be sure that CEL-SCI will have enough cash to stay in business until January 2010. As is clearly explained in the Company's 10-K filing, CEL-SCI's management is aware of this, and is currently working on licensing agreements (in addition to the two agreements it currently has with Teva P
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
3. CEL-SCI Takes Delivery of New Manufacturing Facility
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
6. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
7. CEL-SCI to Present at the Noble Financial Conference
8. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
9. Mach One Corporation Enters Letter of Intent
10. Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
11. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 Annual Meeting of Stockholders on May 4, 2015 ... for the Annual Meeting represents a change of more ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Inc. (Nasdaq: ANDS ) announced today that it ... conference on Thursday, April 2, 2009 at 2:00 p.m. EDT ... the Millennium Broadway Hotel in New York City. Steve ... provide an overview of Anadys and its clinical programs: ANA598 ...
... March 26 NATURAL FUELS INDUSTRIES, INC. (Pink ... raised their rating for the Company to "Fully Compliant", ... categorizes all securities trading over-the-counter into easily identifiable tiers ... public information available in a timely manner. Subsequent ...
... R&D Directions honors Dr. Sellers, pioneering work in human ... KNDL ), a leading, global full-service clinical research ... and General Manager of the company,s Early Stage Unit ... People in R&D" by leading industry publication R&D ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 2Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 3
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... The Nature Conservancy and Conservation International (CI) have ... Rica in one of the largest debt-for-nature swaps in ... Costa Ricas most critically threatened tropical forests, with the ... and Costa Rica spending that amount on tropical forest ...
... in the expression of genes may be the reason why ... quickly develop a tolerance, biologists at The University of Texas ... graduate student Yan Wang, used the fruit fly Drosophila melanogaster ... becomes tolerant to sedation with organic solvent inhalants. The ...
... Frankel, a scientific imagist and researcher at Harvard ... the recipient of the 2007 Lennart Nilsson Award. ... exquisite works of art and crystal-clear scientific illustrations ... public and scientific community alike. The Lennart ...
Cached Biology News:Costa Rica, US announce historic debt-for-nature swap 2Costa Rica, US announce historic debt-for-nature swap 3Tolerance to inhalants may be caused by changes in gene expression 2Lennart Nilsson Award 2007 2
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
... UN-SCAN-IT gel Software converts any scanner into ... numerous options and features, the basic operation ... JPEG, PCX, BMP, etc.) into pixel density ... steps. Turn your scanner ...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... tubes and 96 well plates. microCLEAN is an ... a half spin DNA cleanup reagent. It can ... type of double stranded DNA, efficiently removing reaction ... or unlabelled). It is therefore ideally suited to ...
Biology Products: